Midwest Trust’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.85M Sell
26,617
-241
-0.9% -$63.5K 0.09% 172
2026
Q2
$6.09M Sell
26,858
-52
-0.2% -$9.26K 0.07% 199
2026
Q1
$4.64M Buy
26,910
+28
+0.1% +$5.19K 0.06% 217
2025
Q4
$5.36M Sell
26,882
-165
-0.6% -$29.9K 0.07% 205
2025
Q3
$4.23M Buy
27,047
+906
+3% +$144K 0.06% 222
2025
Q2
$3.97M Buy
+26,141
New +$3.49M 0.05% 222

Other funds holding CRL

Midwest Trust's CRL Position: Q3 2026 in Review

Midwest Trust reduced its Charles River Laboratories (CRL) stake by 0.9% in Q3 2026, selling an estimated $63.5K and leaving 26,617 shares worth $7.85M. The position accounts for 0.09% of the portfolio, ranked #172.

Midwest Trust first reported a position in CRL in Q2 2025 and has held it in 6 quarters since. 91 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Midwest Trust held 26,617 shares of Charles River Laboratories worth $7.85M as of Q3 2026.
  • Midwest Trust sold 241 Charles River Laboratories shares in Q3 2026, an estimated $63.5K.
  • Charles River Laboratories made up 0.09% of Midwest Trust's portfolio in Q3 2026, its #172 holding.
  • Midwest Trust first reported a position in Charles River Laboratories in Q2 2025 and has held it in 6 quarters since.
  • 91 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Midwest Trust's 13F filing for Q3 2026, filed 22 Oct 2026.